Montag A & Associates Inc Intellia Therapeutics, Inc. Transaction History
Montag A & Associates Inc
- $2.09 Billion
- Q3 2024
A detailed history of Montag A & Associates Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Montag A & Associates Inc holds 300 shares of NTLA stock, worth $2,850. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 300
-0.0%
Holding current value
$2,850
Previous $6,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NTLA
# of Institutions
316Shares Held
91.7MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$116 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$91.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$91.2 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$48.9 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$47 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $722M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...